CTAs keep buying Treasuries, gold longs face stop-loss risk: BofA
EMERYVILLE, Calif. - Estrella Immunopharma, Inc. (NASDAQ: ESLA), a biopharmaceutical company focused on T-cell therapies for cancer and autoimmune diseases, has announced a private investment in public equity (PIPE) financing deal expected to generate approximately $3.35 million. The agreement, dated May 30, 2025, involves issuing over 2.3 million shares at $1.50 each, above the last reported sale price of $1.00 per share. According to InvestingPro data, the company currently maintains a market capitalization of $35 million and holds more cash than debt on its balance sheet, though its short-term obligations exceed liquid assets.
The proceeds from the PIPE are earmarked for advancing Phase I of the STARLIGHT-1 clinical trial, which evaluates EB103, Estrella’s CD19-Redirected ARTEMIS® T-cell therapy for adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). Cheng Liu, CEO of Estrella Immunopharma, expressed confidence from investors as a sign of their belief in the potential of the company’s ARTEMIS® T-cell therapy platform. InvestingPro analysis shows analysts have set an ambitious price target of $16 per share, though they anticipate the company will not be profitable this year. Get access to 6 more exclusive InvestingPro Tips and comprehensive financial metrics to make informed investment decisions.
The closing of the PIPE financing is contingent on customary closing conditions. The securities offered have not been registered under the Securities Act of 1933 and are sold exempt from registration requirements, with a commitment from the company to file a registration statement with the SEC for the resale of the securities issued.
EB103, Estrella’s leading product candidate, is designed to target CD19, a protein found on the surface of most B-cell leukemias and lymphomas. Estrella is also developing EB104, which targets both CD19 and CD22, another protein common in B-cell malignancies.
This financial move is part of Estrella Immunopharma’s broader strategy to leverage the human immune system in the fight against cancer and other diseases. The information in this article is based on a press release statement from Estrella Immunopharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.